Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Travel Med Infect Dis ; 41: 102028, 2021.
Article in English | MEDLINE | ID: mdl-33737162

ABSTRACT

BACKGROUND: Antimicrobial resistance is increased by international mobility. We present data about intestinal colonization of travelers departing from a middle-income country. METHODS: Travelers were recruited from 2015 to 2019, collected an anal stool specimen and answered a questionnaire before and after travel. Enterobacterales isolates were investigated for antimicrobial resistance; extended-spectrum beta-lactamase (ESBL) and carbapenemase production; plasmid-encoded cephalosporinases (pAmpC), plasmid-mediated quinolone resistance (PMQR) and mcr genes by PCR and sequencing; and association with travel related variables. RESULTS: Among 210 travelers, 26 (12%) carried multidrug-resistant Enterobacterales (MDR-E) and 18 (9%) ESBL-producing Enterobacterales (ESBL-E) before travel, with an increased prevalence from 1% to 11% over the study years. Acquisition of MDR-E and ESBL-E occurred in 59 (32%) and 43 (22%) travelers, respectively, mostly blaCTX-M-15 carrying Escherichia coli. One traveler acquired one isolate carrying blaOXA-181 gene, and two others, isolates carrying mcr-1. PMQR were detected in 14 isolates of returning travelers. The risk of MDR-E acquisition was higher in Southeast Asia and the Indian subcontinent, and after using antimicrobial agents. CONCLUSION: We describe an increasing pre-travel prevalence of ESBL-E colonization in subjects departing from this middle-income country over time. Travel to known risk areas and use of antimicrobial agents during travel were associated with acquisition of MDR-E. Travel advice is critical to mitigating this risk, as colonization by MDR-E may raise the chances of antimicrobial-resistant infections.


Subject(s)
Anti-Bacterial Agents , Travel , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Brazil/epidemiology , Drug Resistance, Bacterial/genetics , Humans , Travel-Related Illness , beta-Lactamases/genetics
2.
Mem Inst Oswaldo Cruz ; 111(9): 551-8, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27653359

ABSTRACT

Carbapenem-resistance mechanisms are a challenge in the treatment of Pseudomonas aeruginosa infections. We investigated changes in P. aeruginosa carbapenem-resistance determinants over a time period of eight years after the emergence of São Paulo metallo-ß-lactamase in a university hospital in Rio de Janeiro, Brazil. Patients admitted to the intensive care unit (ICU) were screened for P. aeruginosa colonisation and followed for the occurrence of infections from April 2007 to April 2008. The ICU environment was also sampled. Isolates were typed using random amplified polymorphic DNA, pulsed-field gel electrophoresis and multilocus sequence typing. Antimicrobial susceptibility was determined by disk diffusion and E-test, production of carbapenemases by a modified-CarbaNP test and presence of carbapenemase-encoding genes by polymerase chain reaction. Non-carbapenemase resistance mechanisms studied included efflux and AmpC overexpression by PAßN and cloxacillin susceptibility enhancement, respectively, as well as oprD mutations. From 472 P. aeruginosa clinical isolates (93 patients) and 17 isolates from the ICU environment, high genotypic diversity and several international clones were observed; one environment isolate belonged to the blaSPM-1 P. aeruginosa epidemic genotype. Among isolates from infections, 10 (29%) were carbapenem resistant: none produced carbapenemases, three exhibited all non-carbapenemase mechanisms studied, six presented a combination of two mechanisms, and one exclusively displayed oprD mutations. Carbapenem-resistant P. aeruginosa displayed a polyclonal profile after the SPM-1 epidemic genotype declined. This phenomenon is connected with blaSPM-1 P. aeruginosa replaced by other carbapenem-resistant pathogens.


Subject(s)
Carbapenems/pharmacology , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/enzymology , beta-Lactam Resistance/genetics , beta-Lactamases/biosynthesis , Anti-Bacterial Agents/pharmacology , DNA, Bacterial/genetics , Disk Diffusion Antimicrobial Tests , Electrophoresis, Gel, Pulsed-Field , Genotype , Hospitals, University , Humans , Intensive Care Units , Multilocus Sequence Typing , Polymerase Chain Reaction , Prospective Studies , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/genetics , beta-Lactam Resistance/drug effects
3.
Mem. Inst. Oswaldo Cruz ; 111(9): 551-558, Sept. 2016. tab, graf
Article in English | LILACS | ID: lil-794722

ABSTRACT

Carbapenem-resistance mechanisms are a challenge in the treatment of Pseudomonas aeruginosa infections. We investigated changes in P. aeruginosa carbapenem-resistance determinants over a time period of eight years after the emergence of São Paulo metallo-β-lactamase in a university hospital in Rio de Janeiro, Brazil. Patients admitted to the intensive care unit (ICU) were screened for P. aeruginosa colonisation and followed for the occurrence of infections from April 2007 to April 2008. The ICU environment was also sampled. Isolates were typed using random amplified polymorphic DNA, pulsed-field gel electrophoresis and multilocus sequence typing. Antimicrobial susceptibility was determined by disk diffusion and E-test, production of carbapenemases by a modified-CarbaNP test and presence of carbapenemase-encoding genes by polymerase chain reaction. Non-carbapenemase resistance mechanisms studied included efflux and AmpC overexpression by PAβN and cloxacillin susceptibility enhancement, respectively, as well as oprD mutations. From 472 P. aeruginosa clinical isolates (93 patients) and 17 isolates from the ICU environment, high genotypic diversity and several international clones were observed; one environment isolate belonged to the blaSPM-1 P. aeruginosa epidemic genotype. Among isolates from infections, 10 (29%) were carbapenem resistant: none produced carbapenemases, three exhibited all non-carbapenemase mechanisms studied, six presented a combination of two mechanisms, and one exclusively displayed oprD mutations. Carbapenem-resistant P. aeruginosa displayed a polyclonal profile after the SPM-1 epidemic genotype declined. This phenomenon is connected with blaSPM-1 P. aeruginosa replaced by other carbapenem-resistant pathogens.


Subject(s)
Humans , beta-Lactam Resistance/genetics , beta-Lactamases/biosynthesis , Carbapenems/pharmacology , Pseudomonas aeruginosa/enzymology , Pseudomonas Infections/microbiology , Anti-Bacterial Agents/pharmacology , beta-Lactam Resistance/drug effects , Disk Diffusion Antimicrobial Tests , DNA, Bacterial/genetics , Electrophoresis, Gel, Pulsed-Field , Genotype , Hospitals, University , Intensive Care Units , Multilocus Sequence Typing , Polymerase Chain Reaction , Prospective Studies , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/genetics
4.
Microb Drug Resist ; 19(3): 216-23, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23336529

ABSTRACT

The main objective of this study was to assess the frequency and possible sources of colonization and infection by Acinetobacter in the intensive care unit (ICU) of a university hospital in Rio de Janeiro, Brazil, and characterize the isolates for relatedness to internationally and locally disseminated lineages. Patients consecutively admitted to the ICU from April 2007 to April 2008 were screened for colonization and infection. Species were identified by rpoB sequencing. The presence of acquired and intrinsic carbapenemase genes was assessed by polymerase chain reaction (PCR). Strains were typed by random amplification of polymorphic DNA (RAPD)-PCR, pulsed-field gel electrophoresis, and multilocus sequence typing (MLST) using the schemes hosted at the University of Oxford (UO) and Institut Pasteur (IP). Of 234 patients, 98 (42%) had at least one specimen positive for the Acinetobacter isolate, and 24 (10%) had infection. A total of 22 (92%) infections were caused by Acinetobacter baumannii and one each (4%) by Acinetobacter nosocomialis and Acinetobacter berezinae. A. baumannii isolates from 60 patients belonged to RAPD types that corresponded to MLST clonal complexes (CCs) 109/1 (UO/IP scheme, known as International Clone I), CC 110/110 (UO/IP), CC 113/79 (UO/IP), and CC 104/15 (UO/IP). Most CCs were carbapenem resistant and carried the bla(OXA-23)-like gene. Strains were introduced by patients transferred from other wards of the same hospital (11 patients, 18%) or acquired from cross-transmission within the ICU (49 patients, 82%). A. nosocomialis lineage sequence type 260 colonized 10% of the whole study population. A. baumannii have become established in this hospital as a part of a global epidemic of successful clones. Once introduced into the hospital, such clones have become entrenched among patients in the ICU.


Subject(s)
Acinetobacter Infections/epidemiology , Acinetobacter baumannii/isolation & purification , Anti-Bacterial Agents/pharmacology , Intensive Care Units , Acinetobacter/drug effects , Acinetobacter/genetics , Acinetobacter/isolation & purification , Acinetobacter Infections/microbiology , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/genetics , Bacterial Proteins/genetics , Bacterial Typing Techniques , Brazil , Carbapenems/pharmacology , Cohort Studies , Cross Infection/epidemiology , Cross Infection/microbiology , Drug Resistance, Bacterial , Electrophoresis, Gel, Pulsed-Field , Hospitals, University , Humans , Multilocus Sequence Typing , Polymerase Chain Reaction , Prospective Studies , Random Amplified Polymorphic DNA Technique , beta-Lactamases/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...